mirvetuximab,Luveltamab tazevibulin
immunogen,Sutro Biopharma
['mirvetuximab', 'gyn']
 is the winner of this gyn onc #asco23 session. interesting data for a new anti-fra adc (luveltamab). despite early phase study, a clear efficacy signal at both dose levels tested. 3 out of 4 patients though has grade 3 neutropenia. a mirvetuximab antagonist? 
Ασυνάρτητος και ημιτελής. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.